Findings

What do systematic reviews say?

3 questions · 4 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 75%Low 1 · 25%Moderate 0 · 0%High 0 · 0%

Recurrence · AGW in non‐immunocompromised adults

Imiquimod showed no clear difference in recurrence during compared with any other patient‐applied treatment (low certainty).

1 finding from 1 review

Imiquimod for anogenital warts in non‐immunocompromised adults 2014 · Cochrane Headline outcomes only
RR 0.49 [0.21, 1.11]
1 study · 30 participants
Low

Recurrence · AGW in non‐immunocompromised adults

It is very uncertain whether imiquimod changes recurrence during compared with any other provider‐administered treatment (very low certainty).

2 findings from 1 review

Imiquimod for anogenital warts in non‐immunocompromised adults 2014 · Cochrane Headline outcomes only
RR 0.24 [0.1, 0.56]
1 study · 192 participants
Very low
Imiquimod for anogenital warts in non‐immunocompromised adults 2014 · Cochrane Headline outcomes only
RR 0.71 [0.4, 1.25]
1 study · 53 participants
Very low

Recurrence · AGW in non‐immunocompromised adults

It is very uncertain whether imiquimod changes recurrence during compared with placebo (very low certainty).

1 finding from 1 review

Imiquimod for anogenital warts in non‐immunocompromised adults 2014 · Cochrane Headline outcomes only
RR 2.76 [0.7, 10.91]
4 studies · 286 participants
Very low